ACT
Dr. P. Collignon, Mr P. Southwell
Department of Microbiology
Royal Canberra Hospital
PO Box 11
WODEN, ACT 2606
Phone: (02) 6244 2425
Email: peter.collignon@dpa.act.gov.au

NORTHERN TERRITORY
Dr G. Lum
Microbiology Department
Royal Darwin Hospital
CASUARINA, NT
Phone: (08) 8922 8834, Fax (08) 8922 8843
Email: glum@ozemail.com.au

References

Changes to the Editorial team
The production team for CDI has recently farewelled the Editor Eddie O’Brien, and welcomed our new Editor, Jenny Thomson. Eddie’s valuable input, skills and expertise, as well as his cheerful interaction as a team member will be missed. We wish Eddie well in his new position and thank him for his contribution to CDI. Jenny Thomson comes to us with qualifications and experience that will greatly benefit CDI. We welcome Jenny to the team and look forward to her ongoing input to the quality and development of the publication.

Australian recommendations for the influenza vaccine composition for the year 2000 season
The meeting of the Australian Influenza Vaccine Committee (AIVC) was convened on 7 October 1999 and reconvened on 9 November.

Having considered the information on international surveillance by the WHO, and recent epidemiological data and strain characterisation presented at both AIVC meetings, the Committee decided that the composition of vaccines for the year 2000 season should be as follows:

- **A (H3N2):** a A/Sydney/5/97 (H3N2) - like strain, 15 µg HA per dose
- **A (H1N1):** a A/New Caledonia/20/99 (H1N1) - like strain, 15 µg HA per dose
- **B:** a B/Beijing/184/93 - like strain, 15 µg HA per dose

It was also determined that the following viruses are suitable vaccine strains:
- A/Sydney/5/97(IVR-108 and RESVIR-13) are A/Sydney/5/97 (H3N2)-like strains
- A/New Caledonia/20/99 (IVR-116) is an A/New Caledonia/20/99 (H1N1)-like strain
- B/Yamanashi/166/98 is a B/Beijing/184/93-like strain